According to a comprehensive literature study, COVID-19 neurological problems, such as fatigue, headache, and cognitive impairment, are ultimately reversible. Other neurological conditions, such as Parkinson''s disease, are also discussed.
Patients who have more severe COVID-19 cases, who are older, or have pre-existing illnesses are more likely to experience these neurological illnesses.
Molecular imaging with PET or SPECT has been used to determine how COVID-19 affects the brain; however, these scans often show conflicting results. Researchers have done a comprehensive, systematic and critical review of molecular imaging studies in neuropsychiatric COVID-19 cases.
The findings were grouped according to neurological symptoms and their degree of development over time. encephalitis, Parkinsonism, and other neurodegenerative illnesses, focal symptoms/lesions, and encephalopathy, as well as other chronic symptoms. This assisted the researchers in understanding the potential underlying (and most likely diverse) symptoms, and in discovering gaps in the PET and SPECT literature.
According to Philipp T. Meyer, the doctor''s department of nuclear medicine at the Medical Center University of Freiburg, Germany, there are no evidence of significant and irreversible brain damage, except for brain infarcts and bleedings. From our perspective, in the vast majority of cases, there is no reason to assume that diagnosed impairments will be permanent and not responsive to treatment.
What are the implications of this study on the future of molecular imaging of COVID-19 neurological symptoms? First, there is a clear need for further well-designed studies. These should be prospective, recruit larger patient cohorts, follow accepted syndrome or stage definitions, and use appropriate methodology, according to Jonas A. Hosp, MD. In the future, caring research of COVID-19 populations will be of great interest.
Second, there are several potential clinical applications of molecular imaging in COVID-19 individuals with cognitive or neurological impairment. It may be that COVID-19 has unmasked or delayed a pre-existing neurological disease like Parkinsons or Alzheimers, according to Meyer. Molecular imaging may be used to identify these patients.